Aura Biosciences (NASDAQ:AURA) Shares Climb 1.6% - Here's What Happened

Key Points

• Aura Biosciences shares rose 1.6% to $6.40, with trading volume slightly below average. The company has a market capitalization of approximately $664 million.
• Analyst sentiment remains mixed: Wall Street Zen downgraded the stock to “sell,” while HC Wainwright maintained a “buy” rating but cut its price target to $18. The consensus rating is “Hold,” with a $17.50 target.
• Aura reported a quarterly loss of $0.48 per share, missing estimates by $0.10, and analysts expect a full-year loss of $1.61 per share. Institutional investors and hedge funds own 96.75% of the stock.

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) traded up 1.6% during trading on Wednesday. The company traded as high as $6.41 and last traded at $6.40. Approximately 541,814 shares were traded during mid-day trading, a decline of 4% from the average session volume of 562,662 shares. The stock had previously closed at $6.30.

Analyst Ratings Changes

AURA has been the topic of several research analyst reports. Wall Street Zen lowered shares of Aura Biosciences from a "hold" rating to a "sell" rating in a research note on Sunday, August 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of Aura Biosciences in a research report on Monday, October 12th. Finally, HC Wainwright decreased their price objective on shares of Aura Biosciences from $24.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, August 11th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $17.50.

Aura Biosciences Trading Up 1.6%

The stock has a market cap of $663.71 million, a PE ratio of -3.66 and a beta of 0.41. The business has a 50 day moving average of $6.74 and a 200-day moving average of $6.68.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.10). Research analysts expect that Aura Biosciences, Inc. will post -1.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Aura Biosciences

A number of institutional investors have recently modified their holdings of AURA. Parallel Advisors LLC grew its position in Aura Biosciences by 130.4% during the 1st quarter. Parallel Advisors LLC now owns 5,665 shares of the company's stock worth $38,000 after purchasing an additional 3,206 shares during the last quarter. Legal & General Group Plc acquired a new position in Aura Biosciences in the second quarter valued at $29,000. Wellington Management Group LLP increased its stake in Aura Biosciences by 3.6% in the second quarter. Wellington Management Group LLP now owns 132,122 shares of the company's stock valued at $938,000 after purchasing an additional 4,579 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Aura Biosciences by 21.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 29,722 shares of the company's stock valued at $183,000 after purchasing an additional 5,168 shares during the period. Finally, Integrated Wealth Concepts LLC acquired a new position in Aura Biosciences in the second quarter valued at $54,000. 96.75% of the stock is owned by institutional investors and hedge funds.

About Aura Biosciences

Aura Biosciences, Inc NASDAQ: AURA is a clinical-stage biotechnology company developing targeted therapies for cancer. The company's platform is designed to use tumor-targeting virus-like particles to selectively bind to cancer cells and deliver therapeutic payloads, with the goal of treating tumors while limiting damage to surrounding healthy tissue.

Aura's lead product candidate is AU-011, also known as belzupacap sarotalocan, an investigational therapy being developed for primary choroidal melanoma, a form of eye cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.